GAMMA Investing’s Jade Biosciences JBIO Stock Holding History

GAMMA Investing’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17.7K	Buy	1,257 +341	+37%	+$6.84K	﹤0.01%	3021
2026 Q2	$20.4K	Buy	916 +254	+38%	+$5.3K	﹤0.01%	2827
2026 Q1	$9.3K	Buy	662 +305	+85%	+$4.42K	﹤0.01%	3102
2025 Q4	$5.51K	Buy	357 +175	+96%	+$2.05K	﹤0.01%	3238
2025 Q3	$1.57K	Buy	182 +55	+43%	+$449	﹤0.01%	3512
2025 Q2	$1.27K	Buy	+127	New	+$4.32K	﹤0.01%	3490
2024 Q3	–	Sell	-2	Closed	-$133	–	3585
2024 Q2	$133	Sell	2 -1	-33%	-$663	﹤0.01%	3394
2024 Q1	$2.78K	Buy	3 +1	+50%	+$764	﹤0.01%	2636
2023 Q4	$1.54K	Buy	+2	New	+$1.02K	﹤0.01%	2660

Other funds holding JBIO

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's JBIO Position: Q3 2026 in Review

GAMMA Investing increased its Jade Biosciences (JBIO) stake by 37% in Q3 2026, buying an estimated $6.84K and bringing the position to 1,257 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

GAMMA Investing first reported a position in JBIO in Q4 2023 and has held it in 9 quarters since. The position peaked at $20.4K in Q2 2026. 5 funds tracked by Wall St. Rank hold JBIO as of Q3 2026.

GAMMA Investing held 1,257 shares of Jade Biosciences worth $17.7K as of Q3 2026.
GAMMA Investing bought 341 Jade Biosciences shares in Q3 2026, an estimated $6.84K.
Jade Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3021 holding.
GAMMA Investing first reported a position in Jade Biosciences in Q4 2023 and has held it in 9 quarters since.
GAMMA Investing's Jade Biosciences position peaked at $20.4K in Q2 2026.
5 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.